Dexchlorpheniramine API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Dexchlorpheniramine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Dexchlorpheniramine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Dexchlorpheniramine API 25523-97-1?

Description:
Here you will find a list of producers, manufacturers and distributors of Dexchlorpheniramine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Dexchlorpheniramine 
Synonyms:
dexclorfeniramina  
Cas Number:
25523-97-1 
DrugBank number:
DB13679 
Unique Ingredient Identifier:
3Q9Q0B929N

General Description:

Dexchlorpheniramine, identified by CAS number 25523-97-1, is a notable compound with significant therapeutic applications. Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

Classification:

Dexchlorpheniramine belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton, classified under the direct parent group Pheniramines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Pyridines and derivatives class, specifically within the Pheniramines subclass.

Categories:

Dexchlorpheniramine is categorized under the following therapeutic classes: Agents that reduce seizure threshold, Antihistamines for Systemic Use, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Pyridines, QTc Prolonging Agents, Stereoisomerism, Substituted Alkylamines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Dexchlorpheniramine is a type of Anti-allergy agents


Anti-allergy agents, also known as antihistamines, are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of allergies. These substances work by blocking the effects of histamine, a chemical released by the body's immune system during an allergic reaction.

Antihistamines act on histamine receptors, preventing them from binding to target cells and thus inhibiting the release of allergic symptoms such as itching, sneezing, and watery eyes. These APIs can be classified into two generations based on their characteristics.

First-generation antihistamines, such as diphenhydramine and chlorpheniramine, are known for their sedative properties due to their ability to cross the blood-brain barrier. Although effective in relieving allergy symptoms, they often cause drowsiness, impairing daily activities.

Second-generation antihistamines, including cetirizine and loratadine, were developed to address the sedative side effects of their predecessors. These newer APIs have a higher selectivity for peripheral histamine receptors and a reduced ability to penetrate the central nervous system, resulting in reduced sedation.

Anti-allergy APIs are available in various formulations, including oral tablets, liquids, nasal sprays, and eye drops. They are widely used to alleviate allergic reactions caused by pollen, dust mites, pet dander, and other environmental allergens. These agents provide relief from symptoms such as itching, runny nose, congestion, and hives.

In summary, anti-allergy agents are a vital category of APIs used to manage allergic reactions. They block the effects of histamine, providing relief from allergy symptoms. The development of second-generation antihistamines has significantly reduced sedative side effects, improving patient comfort. These APIs are available in different formulations, catering to the diverse needs of allergy sufferers.